Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT04295018 Recruiting - Multiple Myeloma Clinical Trials

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Start date: October 23, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patients.

NCT ID: NCT04287660 Recruiting - Multiple Myeloma Clinical Trials

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Start date: October 19, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients

NCT ID: NCT04275583 Recruiting - Multiple Myeloma Clinical Trials

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Start date: May 28, 2020
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in patients with advanced malignant tumors.

NCT ID: NCT04272151 Recruiting - Multiple Myeloma Clinical Trials

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Start date: December 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

NCT ID: NCT04271930 Recruiting - Multiple Myeloma Clinical Trials

Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

This randomized, controlled study will compare Mindfulness Awareness Practices for Insomnia (MAP-I) to sleep health education (SHE) in subjects receiving autologous hematopoietic cell transplant for multiple myeloma.

NCT ID: NCT04271644 Recruiting - Multiple Myeloma Clinical Trials

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Start date: April 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

NCT ID: NCT04268498 Recruiting - Multiple Myeloma Clinical Trials

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

ADVANCE
Start date: February 11, 2020
Phase: Phase 2
Study type: Interventional

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).

NCT ID: NCT04268199 Recruiting - Myeloma Clinical Trials

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

EASE
Start date: May 29, 2020
Phase: Phase 2
Study type: Interventional

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

NCT ID: NCT04260490 Recruiting - Multiple Myeloma Clinical Trials

Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.

MYELODOM
Start date: November 19, 2019
Phase:
Study type: Observational

Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM. The French West Indies departments of Guadeloupe and Martinique are characterized by a wide use of pesticides related to bananas plantation, particularly chlordecone which has been classified by IARC as possibly carcinogenic and has recognized hormonal properties (endocrine disruptor). The objective of this study is to measure the association between exposure to pesticide and other environmental factors in the occurrence of MM in Guadeloupe and Martinique and to estimate the proportion of cases of MM attributable to pesticide exposure. Genetic susceptibility markers and their links to environmental factors will be subsequently studies from blood samples collection.

NCT ID: NCT04240054 Recruiting - Multiple Myeloma Clinical Trials

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients

VICD
Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label phase II study with a safety lead-in phase.